Procter & Gamble's
The consumer products giant earned $1.26 per share, up 21% from the year before. Net sales increased by 13%, and organic sales -- which exclude acquisitions, divestitures, and the foreign exchange impact -- were up 7%. What's more, gross margin increased by a significant 180 basis points, not including restructuring charges.
While most of the company's categories were strong performers, the Prilosec story is the most compelling. Several months ago, P&G took a chance by entering into a licensing agreement with the drug's original maker, AstraZeneca
The move did not sit well with competitors Johnson & Johnson
That didn't stop what is by all accounts an extremely successful Prilosec rollout. In today's conference call (transcript provided by CCBN StreetEvents), CEO A.G. Lafley called it " the obvious highlight of the quarter," which could have produced even stronger results. It sold "faster than anybody thought it would. So, we have a supply chain system that just isn't perfect."
What can we expect from the drug in the future? "We're all smiling here," Lafley said, "because there has been a lot of discussion about Prilosec potential over the last week, as you might imagine. We are not going to know until we get enough initial trials with enough heartburn sufferers and more importantly, until we get enough repurchase."
But the conference call seems to indicate that sales will likely be well above the initial estimates, as management is already looking at the $200 million to $400 million range for the first year alone.
That's a lot of purple pills.
More from The Motley Fool
GM Proved Doubters Wrong in 2017 With a Strong Crossover Lineup
GM surprised the market when it announced strong guidance thanks to a revamped line of crossovers and SUVs. Better still, it delivered on the promises.
Ford's Behind-the-Scenes Focus on Data
Ford’s recent partnerships and small-scale tests could bode well for the future.
Ford's Tumultuous 2017
Ford’s stock languished behind GM throughout 2017. Will 2018 be a turnaround year?